Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing

• Published in: Cancer cell international 2021-01, Vol.21 (1), p.23-23, Article 23
• Main Authors: Shao, Yanxiang, Hu, Xu, Yang, Zhen, Lia, Thongher, Yang, Weixiao, Wu, Kan, Ren, Shangqing, Xiong, Sanchao, Dou, Weichao, Feng, Shuyang, Wang, Yaohui, Liu, Yang, Wu, Kang, Li, Xiang
• Format: Article
• Language: English
• Subjects: Bacillus Calmette-Guerin vaccine; Bacillus Calmette–Guérin; BCG; Biomarkers; Bladder cancer; Cancer therapies; Chemotherapy; DNA damage; DNA damage response and repair; DNA repair; Epigenetics; Epirubicin; Fibroblast growth factor receptor 1; Fibroblast growth factor receptors; Genes; Genetic diversity; Invasiveness; Medical prognosis; Mutation; Next-generation sequencing; p53 Protein; Predictive model; Primary Research; Therapeutic targets; Tumors
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-020-01731-9

To investigate the genetic prognostic factors for the recurrence of non-muscle invasive bladder cancer. The patients underwent transurethral resection of bladder tumor and received bacillus Calmette-Guérin (BCG) or epirubicin. Next-generation sequencing was performed and alterations of genes, pathways, and tumor mutation burden were recorded. Associations between these clinicopathological and genetic variants were estimated, and prognostic factor identified. A total of 58 cases were included in our study, and 46 patients underwent treatment with BCG. FGFR3 was the most frequently altered gene (48%), and more commonly detected in intermediate-risk patients. Univariate Cox analysis demonstrated that 10 genes were significantly correlated with BCG failure, while NEB, FGFR1 and SDHC were independent recurrence predictors. Besides, epigenetic-related gene pathway mutations were negatively correlated with recurrence (hazard ratio: 0.198, P = 0.023). DNA damage response and repair gene alterations were positively correlated with tumor burden, while altered TP53 was most frequent among these genes and significant correlated with high tumor burden. BCG instillation significantly reduced the rate of recurrence compared with epirubicin in this population. Potential biomarkers and therapeutic targets were found with the help of next-generation sequencing; correlations between DDR genes alterations and high tumor mutation burden were also demonstrated.